Last $2.50 USD
Change Today -0.0774 / -3.00%
Volume 1.2K
CLRB On Other Exchanges
As of 2:20 PM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).

cellectar biosciences inc (CLRB) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/2/14 - $9.20
52 Week Low
10/20/14 - $1.76
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

cellectar biosciences inc (CLRB) Related Businessweek News

No Related Businessweek News Found

cellectar biosciences inc (CLRB) Details

Cellectar Biosciences, Inc., a development stage biopharmaceutical company, develops compounds for the treatment and imaging of cancer. Its proprietary product candidates include I-124-CLR1404, a small-molecule, broad-spectrum, and cancer-targeting positron emission tomography (PET) imaging agent that is in Phase II clinical trial for glioblastoma, as well as in Phase I/II clinical trials for approximately 11 solid tumor indications; and CLR1502, a preclinical, cancer-targeted, and non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. The company also develops I-131-CLR1404, a small-molecule, broad-spectrum, and cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells, as well as is in Phase Ib dose-escalation trial for patients with advanced solid tumors; and CLR1404, a cancer-targeted chemotherapy. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.

cellectar biosciences inc (CLRB) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: --
Founder, Chief Scientific Officer and Directo...
Total Annual Compensation: $180.3K
Vice President of Business Development
Total Annual Compensation: $195.8K
Compensation as of Fiscal Year 2013.

cellectar biosciences inc (CLRB) Key Developments

Cellectar Biosciences, Inc. Names Cameron Szakacs as Vice President of Clinical Development

Cellectar Biosciences, Inc. announced the appointment of Cameron Szakacs as Vice President of clinical development. In this newly created position, Dr. Szakacs will report to President and Chief Executive Officer Dr. Simon Pedder and will be responsible for guiding Cellectar's clinical programs, including the ongoing Phase II imaging trial of I-124-CLR1404 in glioblastoma and planned proof of concept trials for 1-131-CLR1404 for the treatment of multiple myeloma and CLR1502 for real time optical imaging in breast cancer surgery.

Cellectar Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Cellectar Biosciences, Inc. reported earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported a net loss of $0.5 million or $0.10 per share compared with a net loss of $1.3 million or $0.46 per share reported for the comparable period in 2013. For the nine months, the company reported net loss of $5.5 million or $1.54 per share compared to a net loss of $6.8 million or $2.47 per share for the nine months ended September 30, 2013.

Cellectar Biosciences, Inc., Q3 2014 Earnings Call, Nov 11, 2014

Cellectar Biosciences, Inc., Q3 2014 Earnings Call, Nov 11, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLRB:US $2.50 USD -0.0774

CLRB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLRB.
View Industry Companies

Industry Analysis


Industry Average

Valuation CLRB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLECTAR BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at